Preclinical safety evaluation of subretinal AAV2.sFlt-1 in non-human primates

C. M. Lai, M. J. Estcourt, R. P. Himbeck, S. Y. Lee, I. Yew-San Yeo, C. Luu, B. K. Loh, M. W. Lee, A. Barathi, J. Villano, C. L. Ang, R. G. Van Der Most, I. J. Constable, D. Dismuke, R. J. Samulski, M. A. Degli-Esposti, E. P. Rakoczy

Research output: Contribution to journalArticleResearchpeer-review

32 Citations (Scopus)

Abstract

We report on the long-term safety of AAV2.sFlt-1 (a recombinant adeno-associated virus serotype 2 carrying the soluble form of the Flt-1 receptor) injection into the subretinal space of non-human primates. Levels of sFlt-1 protein were significantly higher (P0.05) in the vitreous of four out of five AAV2.sFlt-1-injected eyes. There was no evidence of damage to the eyes of animals that received subretinal injections of AAV2.sFlt-1; ocular examination showed no anterior chamber flare, normal fundus and electroretinography responses equivalent to those observed before treatment. Notably, immunological analysis demonstrated that gene therapy involving subretinal injection of AAV2.sFlt-1 does not elicit cell-mediated immunity. Biodistribution analysis showed that AAV2.sFlt-1 could be detected only in the eye and not in the other organs tested. These data indicate that gene therapy with subretinal AAV2.sFlt-1 is safe and well tolerated, and therefore promising for the long-term treatment of neovascular diseases of the eye.

Original languageEnglish
Pages (from-to)999-1009
Number of pages11
JournalGene Therapy
Volume19
Issue number10
DOIs
Publication statusPublished - 1 Oct 2012
Externally publishedYes

Keywords

  • Immunology
  • Neovascularization
  • Retinal diseases

Cite this

Lai, C. M., Estcourt, M. J., Himbeck, R. P., Lee, S. Y., Yew-San Yeo, I., Luu, C., Loh, B. K., Lee, M. W., Barathi, A., Villano, J., Ang, C. L., Van Der Most, R. G., Constable, I. J., Dismuke, D., Samulski, R. J., Degli-Esposti, M. A., & Rakoczy, E. P. (2012). Preclinical safety evaluation of subretinal AAV2.sFlt-1 in non-human primates. Gene Therapy, 19(10), 999-1009. https://doi.org/10.1038/gt.2011.169